VTORIChNAYa PROFILAKTIKA IShEMIChESKOGO INSUL'TA: KOGDA BEZOPASNOST' VAZhNA TAK ZhE KAK EFFEKTIVNOST' (NA PRIMERE TERAPII STATINAMI)?
- Authors: Yanishevskiy SN1,2, Skiba Y.B1, Puchek VD3, Buchin IM3
-
Affiliations:
- ВМедА им. С.М. Кирова
- НМИЦ им. В.А. Алмазова
- Филиал №3 3 ЦВКГ им. А.А. Вишневского
- Issue: Vol 38, No 3 (Прил) (2019)
- Pages: 180-182
- Section: Articles
- URL: https://journal-vniispk.ru/RMMArep/article/view/26178
- DOI: https://doi.org/10.17816/rmmar26178
- ID: 26178
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S N Yanishevskiy
ВМедА им. С.М. Кирова; НМИЦ им. В.А. АлмазоваСанкт-Петербург
Ya B Skiba
ВМедА им. С.М. КироваСанкт-Петербург
V D Puchek
Филиал №3 3 ЦВКГ им. А.А. ВишневскогоОдинцово
I M Buchin
Филиал №3 3 ЦВКГ им. А.А. ВишневскогоОдинцово
References
- Диагностика и коррекция нарушений липидного обмена с Целью профилактики и лечения атеросклероза. Российские рекомендации, VI пересмотр // Российский кардиологический журнал. - №3. - 2017. - 5-22.
- Кузьмина И.М., Гиляревский С.Р., Голшмид М.В., Захарова Г.Ю., Синицина И.И. Применение питавастатина у лиц пожилого и старческого возраста: оптимальное соотношение пользы и риска // Атеротромбоз. - 2016. - №2. - URL: https://cyberleninka. ru/article/n/primenenie-pitavastatina-u-lits-pozhilogo-i-starcheskogo vozrasta-optimalnoe-sootnoshenie-polzy-i-riskа.
- ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) // European Heart Journal. https://doi.org/10.1093/eurheartj/ehz455.
- Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C., Blackwell L., Emberson J., Holland L.E. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials // Lancet. - 2010. - № 376. - 1670-1681.
- Clegg A., Young J., Lliffe S. Frailty in elderly people // Lancet. -2013. - № 381. - 752-762. Пожилой пациент 4-5
- Francois M. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract // European Heart Journal. - 2018. - № 39. - 2526-2539
- Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S. 2018 AHA/ACC/ AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines // Circulation. - 2018: doi: 10.1161/CIR.0000000000000625.
- Gumprecht J., Gosho M., Budinski D. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia // Diabetes Obes. Metab. - 2011. - № 13. - 1047-1055.
- Hunt D., Young P., Simes J. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart dis- ease are equal to or exceed those seen in younger patients: results from the LIPID trial // Ann. Intern. Med. - 2001. - № 134. - 931-940. LIPID
- Karlson B.W., Palmer M.K., Nicholls S.J. To what extent high-intensity statins reduce low-density lipoprotein cholesterol in each of the four statin benefit groups identified by the 2013 American College of Cardiology/American Heart Association guidelines? A VOYAGER meta-analysis // Atherosclerosis. - 2015: doi: 10.1016/j.atherosclerosis.2015.05.029.
- Kowa Pharmaceutical Europe Co. Ltd. Livazo Consolidated SmPC. Summary of Product Characteristics. http://www.kowapharma-ceuticals.eu/de/assets/dl/Livazo_Consolidated_SmPC_05-12-16.pdf (29 March 2018).
- Linton A., Garber M., Fagan N.K., Peterson M.R. Examination of multiple medication use among TRICARE benefit ciaries aged 65 years and older // J. Manag. Care Pharm. - 2007. - №13. - 155-162.
- Ose L., Budinski D. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia // Curr. Med. Res. Opin. - 2009. - № 25. - 2755-2765.
- Ose L., Budinski D., Hounslow N. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia // Atherosclerosis. - 2010. - № 210. - 202-208.
- Sponseller C.A., Morgan R.E., Kryzhanovski V.A. et al. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial // Clin. Ther. - 2014. - № 36. - 1211-1222.
- Strandberg T.E., Kolehmainen L., Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review // JAMA. - 2014. - № 312. - 1136-1144. Пожилой пациент 4-5
- Weng T.C., Yang Y.H., Lin S.J., Tai S.H. A systematic review and meta-analysis on the therapeutic equivalence of statins // J. Clin. Pharm.Ther. - 2010. - № 2 (35). - 139151.
Supplementary files
